Osteopontin has a protective role in prostate tumor development in mice

被引:9
作者
Danzaki, Keiko [1 ]
Kanayama, Masashi [1 ]
Alcazar, Oscar [1 ]
Shinohara, Mari L. [1 ,2 ]
机构
[1] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27710 USA
关键词
B16; cell; Cancer; Cell migration; Chemokines; NK cell; Osteopontin (OPN); TRAMP; Tumor immunology; INTRACELLULAR OSTEOPONTIN; CANCER; CYTOTOXICITY; PROGRESSION; INTEGRIN; EXPRESSION; SURVIVAL; GROWTH; CELLS; MACROPHAGES;
D O I
10.1002/eji.201646391
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Osteopontin (OPN) is a protein, generally considered to play a pro-tumorigenic role, whereas several reports have demonstrated the anti-tumorigenic function of OPN during tumor development. These opposing anti-and pro-tumorigenic functions are not fully understood. Here, we report that host-derived OPN plays an anti-tumorigenic role in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model and a TRAMP tumor transplant model. Tumor suppression mediated by OPN in Rag2(-/-) mice suggests that OPN is dispensable in the adaptive immune response. We found that host-derived OPN enhanced infiltration of natural killer (NK) cells into TRAMP tumors. The requirement of OPN in NK cell migration towards TRAMP cells was confirmed by an ex vivo cell migration assay. In contrast to TRAMP cells, in vivo B16 tumor development was not inhibited by OPN, and B16 tumors did not show OPN-mediated cell recruitment. It is possible that low levels of chemokine expression by B16 cells do not allow OPN to enhance immune cell recruitment. In addition to demonstrating the anti-tumorigenic role of OPN in TRAMP tumor development, this study also suggests that the contribution of OPN to tumor development depends on the type of tumor as well as the source and isoform of OPN.
引用
收藏
页码:2669 / 2678
页数:10
相关论文
共 40 条
[1]   Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer [J].
Bellahcene, Akeila ;
Castronovo, Vincent ;
Ogbureke, Kalu U. E. ;
Fisher, Larry W. ;
Fedarko, Neal S. .
NATURE REVIEWS CANCER, 2008, 8 (03) :212-226
[2]   Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice [J].
Bourassa, B ;
Monaghan, S ;
Rittling, SR .
CELLULAR IMMUNOLOGY, 2004, 227 (01) :1-11
[3]   Regulation of T-helper-cell lineage development by osteopontin: the inside story [J].
Cantor, Harvey ;
Shinohara, Mari L. .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (02) :137-141
[4]   Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms [J].
Chakraborty, Goutam ;
Jain, Shalini ;
Kundu, Gopal C. .
CANCER RESEARCH, 2008, 68 (01) :152-161
[5]   The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis [J].
Chakraborty, Goutam ;
Jain, Shalini ;
Behera, Reeti ;
Ahmed, Mansoor ;
Sharma, Priyanka ;
Kumar, Vinit ;
Kundu, Gopal C. .
CURRENT MOLECULAR MEDICINE, 2006, 6 (08) :819-830
[6]   Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis [J].
Chiodoni, Claudia ;
Colombo, Mario P. ;
Sangaletti, Sabina .
CANCER AND METASTASIS REVIEWS, 2010, 29 (02) :295-307
[7]   Matricellular Proteins: A Sticky Affair with Cancers [J].
Chong, Han Chung ;
Tan, Chek Kun ;
Huang, Royston-Luke ;
Tan, Nguan Soon .
JOURNAL OF ONCOLOGY, 2012, 2012
[8]   Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties [J].
Christensen, Brian ;
Kazanecki, Christian C. ;
Petersen, Torben E. ;
Rittling, Susan R. ;
Denhardt, David T. ;
Sorensen, Esben S. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (27) :19463-19472
[9]  
Crawford HC, 1998, CANCER RES, V58, P5206
[10]   T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine [J].
Donkor, Moses K. ;
Sarkar, Abira ;
Savage, Peter A. ;
Franklin, Ruth A. ;
Johnson, Linda K. ;
Jungbluth, Achim A. ;
Allison, James P. ;
Li, Ming O. .
IMMUNITY, 2011, 35 (01) :123-134